addS

Showing posts with label Current Partnering. Show all posts
Showing posts with label Current Partnering. Show all posts

Thursday 11 July 2013

Global Business Survey: Alcon Partnering Market Size 2005-2013

This report provides all the information you require to better understand Alcon and its partnering interests and activities over the past seven years.




One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.

The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. 

Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst 

Chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.



To Buy The Copy of This Report Visit:  http://www.marketresearchreports.biz/analysis/170727  




About Us


MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948

Study Report: Actelion Partnering Market Share 2005-2013

This report provides all the information you require to better understand Actelion and its partnering interests and activities over the past seven years.




One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.

The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. 

Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst 

Chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.



To Buy The Copy of This Report Visit:  http://www.marketresearchreports.biz/analysis/170726




About Us


MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948

Monday 8 July 2013

Top Research : Ipsen Partnering 2005-2013 : MarketResearchReports.biz


The Partnering Agreements with Intermune 2005-2013 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.


To Read The Complete Report with  TOC : http://www.marketresearchreports.biz/analysis/170692


This report provides all the information you require to better understand Intermune and its partnering interests and activities over the past seven years.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

This report provides all the information you require to better understand Intermune and its partnering interests and activities over the past seven years.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/

Thursday 6 June 2013

Monoclonal Antibodies Partnering Terms and Agreements Industry Available Through MarketResearchReports.biz


The  Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
                                
This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2007 including financial terms where available including over 700 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.




Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?             
  • What exclusivity is granted? 
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal? 
  • How aresalesand payments audited? 
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
                    
Chapter 3 provides a review of the leading monoclonal antibody deals since 2007. Deals are listed by headline value and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
                            
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of monoclonal antibody deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of monoclonal antibody deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive list and detailed review of monoclonal antibody partnering deals signed and announced since January 2007, by specific technology type. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type, stage of development and therapy type deals. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

Report scope
                          
Monoclonal Antibodies Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.
                                         
Monoclonal Antibodies Partnering Terms & Agreements includes:
                                                        
  • Trends in monoclonal antibodies dealmaking in the biopharma industry since 2007
  • Analysis of monoclonal antibodies deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 700 monoclonal antibodies deal records
  • The leading monoclonal antibodies deals by value since 2007
  • Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2007

In Monoclonal Antibodies Partnering Terms & Agreements, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Monoclonal antibodies type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Monoclonal Antibodies Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 700 monoclonal antibody deals. 




Analyzing actual contract agreements allows assessment of the following:
                                 
  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Monday 13 May 2013

MarketResearchReports.biz Publishes Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech


The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
 
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. 

To Buy a Copy Of This Report: http://www.marketresearchreports.biz/analysis/167593  

This report contains over 2,200 links to online copies of actual preclinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of why companies partner preclinical stage compounds/products.                                                    

Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. 

Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.
 
Chapter 5 provides a review of preclinical stage deal making since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 6 provides a detailed analysis of preclinical stage payment terms including average headline, upfront, milestone and royalty rates for preclinical deals.
 
Chapter 7 provides a review of the leading preclinical stage deal by headline value.

Chapter 8 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of preclinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. 
 


Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 
 
Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2007 organized by stage of development.
 
The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2007.
 
In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.               

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.


Latest Report:

Antibiotics Partnering Terms and Agreements: http://www.marketresearchreports.biz/analysis/167594

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why compani... 

MarketResearchReports.biz Publishes Antibiotics Partnering Terms and Agreements


The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
 
  • Trends in antibiotics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Antibiotics partnering contract documents
  • Top antibiotics deals by value
The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
 

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 
 
This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:
 
  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
                                
This report contains over 180 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


For example, analyzing actual company deals and agreements allows assessment of the following:
 
  • What is actually granted by the agreement to the partner company?               
  • What exclusivity is granted? 
  • What are the precise rights granted or optioned? 
  • What is the payment structure for the deal? 
  • How aresalesand payments audited? 
  • What is the deal term? 
  • How are the key terms of the agreement defined? 
  • How are IPRs handled and owned? 
  • Who is responsible for commercialization? 
  • Who is responsible for development, supply, and manufacture? 
  • How is confidentiality and publication managed? 
  • How are disputes to be resolved? 
  • Under what conditions can the deal be terminated? 
  • What happens when there is a change of ownership? 
  • What sublicensing and subcontracting provisions have been agreed? 
  • Which boilerplate clauses does the company insist upon? 
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of drug dealmaking and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in antibiotics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
                    
Chapter 3 provides a review of the leading antibiotics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
 
Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
 
The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2007.
 
In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
                                                  
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.


Latest Report:

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech: http://www.marketresearchreports.biz/analysis/167595

Provides comprehensive understanding and unprecedented access to discovery, preclinical and clinical stage partnering agreements entered into by the worlds leading biopharma companies  The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or a...

New Report On Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech Available By MarketResearchReports.biz


Provides comprehensive understanding and unprecedented access to discovery, preclinical and clinical stage partnering agreements entered into by the worlds leading biopharma companies 

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 8,000 links to online copies of actual discovery, preclinical and clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery, preclinical and clinical stage deal making and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of why companies partner discovery, preclinical and clinical stage compounds/products.

Chapter 3 provides an overview of discovery, preclinical and clinical stage deals strategy and deal structure including numerous case studies.
Chapter 4 provides an overview of the various payment strategies used in discovery, preclinical and clinical stage deals.

Chapters 5 to 7 provide a review of discovery, preclinical and clinical stage deal making since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 8 provides a detailed analysis of discovery, preclinical and clinical stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals.
 
 
Chapter 9 provides a review of the leading discovery, preclinical and clinical stage deal by headline value.

Chapter 10 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery, preclinical and clinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapters 11 to 13 provides a comprehensive and detailed review of discovery, preclinical and clinical stage partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery, preclinical and clinical stage partnering and deal making since 2007.
In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery, preclinical and clinical stage products and compounds.



Latest Report:

Companion Diagnostics Partnering Terms and Agreements: http://www.marketresearchreports.biz/analysis/19816
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnosti...